[go: up one dir, main page]

DE60014133D1 - Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln - Google Patents

Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln

Info

Publication number
DE60014133D1
DE60014133D1 DE60014133T DE60014133T DE60014133D1 DE 60014133 D1 DE60014133 D1 DE 60014133D1 DE 60014133 T DE60014133 T DE 60014133T DE 60014133 T DE60014133 T DE 60014133T DE 60014133 D1 DE60014133 D1 DE 60014133D1
Authority
DE
Germany
Prior art keywords
neutral
administration
nucleic acids
cationic lipids
medicinal products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60014133T
Other languages
English (en)
Other versions
DE60014133T2 (de
Inventor
Shi Kun Huang
Samuel Zalipsky
Wei-Ming Zhang
Bei Jin
Yolanda P Quinn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of DE60014133D1 publication Critical patent/DE60014133D1/de
Application granted granted Critical
Publication of DE60014133T2 publication Critical patent/DE60014133T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60014133T 1999-10-08 2000-10-10 Lipid zur Verwendung in einer Liposomzusammensetzung zur Abgabe eines Mittels an eine Zelle Expired - Fee Related DE60014133T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15869399P 1999-10-08 1999-10-08
US158693P 1999-10-08
PCT/US2000/027974 WO2001026629A2 (en) 1999-10-08 2000-10-10 Neutral-cationic lipid for nucleic acid and drug delivery

Publications (2)

Publication Number Publication Date
DE60014133D1 true DE60014133D1 (de) 2004-10-28
DE60014133T2 DE60014133T2 (de) 2005-02-03

Family

ID=22569279

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60014133T Expired - Fee Related DE60014133T2 (de) 1999-10-08 2000-10-10 Lipid zur Verwendung in einer Liposomzusammensetzung zur Abgabe eines Mittels an eine Zelle

Country Status (17)

Country Link
US (2) US6974589B1 (de)
EP (1) EP1223916B1 (de)
JP (1) JP2003511405A (de)
KR (1) KR100723852B1 (de)
CN (2) CN1378536A (de)
AT (1) ATE276744T1 (de)
AU (2) AU7868400A (de)
CA (1) CA2386164A1 (de)
DE (1) DE60014133T2 (de)
DK (1) DK1223916T3 (de)
ES (1) ES2226932T3 (de)
HU (1) HUP0203117A3 (de)
IL (1) IL148968A0 (de)
MX (1) MXPA02002899A (de)
NO (1) NO20021615D0 (de)
WO (2) WO2001026625A2 (de)
ZA (1) ZA200202726B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
HUP0201425A3 (en) 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
AU7868400A (en) * 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
LT1771206T (lt) * 2004-05-05 2018-05-25 Silence Therapeutics Gmbh Lipidai, lipidų kompleksai ir jų panaudojimas
EP1935434A1 (de) * 2006-12-19 2008-06-25 Novosom AG Konstruktion und Verwendung von transfektionsverstärkenden Elementen
NZ580980A (en) 2007-04-20 2012-04-27 Sigma Tau Rare Diseases S A Enzymatic anticancer therapy
CN101475503B (zh) * 2008-12-15 2012-02-15 山东大学 一种新型阳离子类脂及其制备方法和应用
EP2532649B1 (de) * 2011-06-07 2015-04-08 Incella GmbH Aminolipide, deren Synthese und Verwendungen davon
EP3586861B1 (de) 2011-06-08 2022-02-09 Translate Bio, Inc. Lipidnanoteilchenzusammensetzungen und verfahren zur mrna-freisetzung
KR101480055B1 (ko) * 2012-04-04 2015-01-09 주식회사 삼양바이오팜 음이온성 약물 전달체의 제조 방법
CN105585598B (zh) * 2014-10-20 2019-02-19 湖南师范大学 甘露糖衍生物阳离子脂质体纳米颗粒的制备方法
IL258625B2 (en) * 2015-10-14 2025-02-01 Bio Path Holdings Inc P–ETHOXY NUCLEIC ACIDS FOR LIPOSOMAL FORMULATIONS
CN107200841B (zh) * 2016-03-17 2019-02-01 华东师范大学 一种培化二酰甘油的合成方法
BR112019005166A2 (pt) 2016-09-16 2019-07-02 Bio Path Holding Inc terapia de combinação com oligonucleotídeos antisense lipossômicos
WO2018193451A1 (en) * 2017-04-19 2018-10-25 Apa- Advanced Technologies Ltd. Fusogenic liposomes, compositions, kits and use thereof for treating cancer
SG11201909649SA (en) 2017-04-19 2019-11-28 Bio Path Holdings Inc P-ethoxy nucleic acids for bcl2 inhibition
CN110636836B (zh) 2017-04-19 2022-12-16 拜奥-帕斯控股股份有限公司 用于stat3抑制的p-乙氧基核酸
CN119792316A (zh) * 2025-03-14 2025-04-11 中国医学科学院医学生物学研究所 磷脂酸在制备预防和/或治疗广谱病毒感染药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5965434A (en) 1994-12-29 1999-10-12 Wolff; Jon A. Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds
DE19521412A1 (de) * 1995-06-14 1996-12-19 Boehringer Mannheim Gmbh Neue kationische und polykationische Amphiphile, diese enthaltende Reagenzien und deren Verwendung
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU1830200A (en) 1998-11-25 2000-06-13 Vanderbilt University Cationic liposomes for gene transfer
AU7868400A (en) 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery

Also Published As

Publication number Publication date
CA2386164A1 (en) 2001-04-19
ATE276744T1 (de) 2004-10-15
AU7868400A (en) 2001-04-23
NO20021615L (no) 2002-04-05
AU8006400A (en) 2001-04-23
ZA200202726B (en) 2003-06-25
EP1223916A2 (de) 2002-07-24
CN1915968A (zh) 2007-02-21
WO2001026629A2 (en) 2001-04-19
JP2003511405A (ja) 2003-03-25
KR100723852B1 (ko) 2007-05-31
HUP0203117A2 (hu) 2003-01-28
KR20020063875A (ko) 2002-08-05
WO2001026625A2 (en) 2001-04-19
DK1223916T3 (da) 2005-01-31
HUP0203117A3 (en) 2005-06-28
ES2226932T3 (es) 2005-04-01
US20050260261A1 (en) 2005-11-24
US6974589B1 (en) 2005-12-13
WO2001026629A3 (en) 2002-05-10
CN1378536A (zh) 2002-11-06
AU778817B2 (en) 2004-12-23
EP1223916B1 (de) 2004-09-22
NO20021615D0 (no) 2002-04-05
DE60014133T2 (de) 2005-02-03
MXPA02002899A (es) 2002-10-23
IL148968A0 (en) 2002-11-10

Similar Documents

Publication Publication Date Title
DE60014133D1 (de) Neutrale-kationische lipide zur verabreichung von nukleinesäuren und arzneimitteln
IL145052A0 (en) Novel phosphorus-containing prodrugs
ATE178067T1 (de) Camptothecinderivate
ES8604090A1 (es) Procedimiento para la preparacion de acidos a,w -dicarboxi- licos
JPS5795989A (en) 2-carbamimidoyl-6-substituted-1-carbadethiapene- 2-em-3-carboxylic acids
EP0488513A3 (de) Verwendung von Dioxabicyclo [3.3.0]octane Derivaten zur Herstellung eines Arzneimittels zur Hemmung des Cholesterinmetabolismus.
MXPA03000547A (es) Uso de derivados de amidas de acido valproico y de acido 2-valproenico, para el tratamiento de manias en trastornos bipolares.
DE69001111D1 (de) Antikrebs-zusammensetzung.
ATE141048T1 (de) Verwendung von polyaminderivaten zur verstärkung der zellularen immunität
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2677023B1 (fr) Derives de coumarine hydrosolubles, leur preparation et leur utilisation comme substrat d'enzyme.
FR2681864B1 (fr) Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE43348T1 (de) Acylierte cytidin-diphosphat-choline, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
PE68299A1 (es) 1,2,3,4-tetrahidroisoquinolinas terapeuticas
MX9804752A (es) Conjugados covalentes de lipidos-acidos fosfonocarboxilicos, la produccion de los mismos asi como su uso como agentes farmaceuticos antivirales .
IT1276161B1 (it) Derivati dell'acido fosfonico ad attivita' inibitrice delle metallopeptidasi
SE9702173L (sv) Nya kolhydrater och deras användning
DE69533833D1 (de) Verfahren zur Herstellung von Indolopyrrolocarbazol-Derivaten
TW345579B (en) Cyanoethylmelamine derivatives and method for producing them
IT1248068B (it) Derivati dell'eseridina ad attivita' anticolinesterasi, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee